Stemirna Therapeutics’ COVID-19 mRNA Vaccine Gets EUA in Laos
Stemirna Therapeutics Co., Ltd, an mRNA drug developer based in Shanghai, has obtained Emergency Use...
Drug
Fujian Cosunter Completes Enrollment for Phase I Study of GST-HG171
China-based Fujian Cosunter Pharmaceutical Co., Ltd (SHE: 300436) announced the completion of the enrollment of...
Alphamab Oncology Updates Clinical Studies for KN046 and KN026 at SABCS 2022
China-based Alphamab Oncology (HKG: 9966) updated the clinical studies for its KN046 and KN026 at...
ASH 2022: China Biotechs Showcase Latest Clinical Trial Results
The American Society of Hematology (ASH) 2022 annual meeting, held online and offline in New...
RemeGen’s RC118 Receives Orphan Drug Designations for Gastric and Pancreatic Cancers
China-based RemeGen Ltd announced that its antibody drug conjugate (ADC) drug candidate RC118 has obtained...
Innovent Biologics Presents Clinical Study Results at ESMO-IO 2022
China-based Innovent Biologics Inc. (HKG: 1801) announced the presentation of two clinical studies at the...
Harbour BioMed Concludes Phase I Study for HBM4003 in Advanced Melanoma
Harbour BioMed (HBM; HKG: 2142), a biotech operating out of the United States, the Netherlands,...
Jacobio’s KRAS G12C Inhibitor JAB-21822 Receives Breakthrough Therapy Designation
The Center for Drug Evaluation (CDE) website indicates that China-based Jacobio Pharmaceuticals Group Co., Ltd’s...
CSPC and Ascletis Get NMPA Approval for COVID-19 Drug Clinical Trials
China-based firms CSPC Pharmaceutical Group Ltd (HKG: 1093) and Ascletis Pharma Inc. (HKG: 1672) both...
Hansoh’s Generic Firazyr Approved for Marketing in China by NMPA
The National Medical Products Administration (NMPA) website indicates that China-based Hansoh Pharmaceutical Group Co., Ltd’s...
NMPA Approves Viatris’ Symfi Lo for HIV-1 Treatment in China
The National Medical Products Administration (NMPA) website indicates that US-based Viatris Inc.’s (NASDAQ: VTRS) Symfi...
SciClone’s Danyelza Approved for Marketing in China by NMPA
The National Medical Products Administration (NMPA) website indicates that SciClone Pharmaceuticals Inc’s (Nasdaq: SCLN) Danyelza...
Enhertu Confirmed as New Standard of Care for Breast Cancer in Phase III Study
AstraZeneca PLC (NASDAQ: AZN) and Daiichi Sankyo (TYO: 4568) released the latest data supporting the...
MicuRx Pharmaceuticals Gains Clinical Trial Approvals for MRX-4 in Europe
Sino-US firm MicuRx Pharmaceuticals Inc. announced receiving clinical trial approvals in France, Greece, Hungary, Italy,...
Beijing Wantai’s Nasal Spray COVID-19 Vaccine Approved for Emergency Use in China
China-based Beijing Wantai Biological Pharmacy Enterprise Co., Ltd (SHA: 603392) announced the inclusion of its...
Junshi Biosciences Files for EMA Approval of Tuoyi for Nasopharyngeal and Esophageal Cancers
China-based Junshi Biosciences (HKG: 1877, SHA: 688180) announced that a market approval filing has been...
WestVac Biopharma’s Recombinant COVID-19 Vaccine Approved for Emergency Use in China
Chengdu-based WestVac Biopharma Co., Ltd announced the inclusion of its recombinant COVID-19 vaccine (Sf9 cells)...
Qilu Pharmaceutical’s QL1604 Plus Chemotherapy Shows Promise in Phase II Study
China-based Qilu Pharmaceutical announced that the results of the Phase II study assessing its QL1604...
Hybio Receives Ethical Approval for HY3000 COVID-19 Nasal Spray Phase II Study
China-based Hybio Pharmaceutical Co., Ltd (SHE: 300199) announced receiving ethical approval for a Phase II...
Clover Biopharmaceuticals’ COVID-19 Vaccine SCB-2019 Included in China’s Emergency Use Program
China-based vaccine specialist Clover Biopharmaceuticals, Ltd (HKG: 2197) announced the inclusion of its COVID-19 vaccine...